Key result
75Se-methyl-nor-cholesterol scintigraphy shows no radiocholesterol uptake in ~86% of adrenocortical carcinomas.
Why the study?
Does 75Se-methyl-nor-cholesterol scintigraphy correlate with endocrine and morphological data in patients with adrenocortical carcinoma?
Observational (n=21)
Does 75Se-methyl-nor-cholesterol scintigraphy correlate with endocrine and morphological data in patients with adrenocortical carcinoma?
While adrenocortical carcinomas typically do not visualize on radiocholesterol scintigraphy, 30% of hypersecreting cases show atypical increased tracer uptake that does not predict biochemical or histological features.
No takes yet. Share an insight, caveat, or question.
Should not yet change scintigraphic evaluation of adrenal masses; hypothesis-generating for atypical uptake in hypersecreting tumors.
Barzon et al. (2001) conducted an observational in Adrenocortical carcinoma (n=21). 75Se-methyl-nor-cholesterol scintigraphy was evaluated on Scintigraphic pattern (radiocholesterol uptake). 75Se-methyl-nor-cholesterol scintigraphy showed no radiocholesterol uptake in 18 of 21 adrenocortical carcinomas, though 30% of hypersecreting tumors exhibited atypical increased tracer uptake.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: